IP Library Granted Patent US 8,071,725
Granted Patent B2
US 8,071,725 · App. 13/010,616 · Granted Dec 6, 2011

Factor VIII polymer conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,725
App. No.
13/010,616
Granted
Dec 6, 2011
Kind
B2
Abstract

The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Claims (19)

1. A composition comprising (a) a Factor VIII molecule; and (b) at least one water soluble polymer bound to said Factor VIII molecule, wherein said water soluble polymer is attached to the Factor VIII via one or more carbohydrate moieties located in the B domain of Factor VIII, wherein said molecule retains at least 50% of native FVIII activity, and said composition is substantially free from albumin.

2. The composition of claim 1 , wherein said water soluble polymer is attached to said carbohydrate moiety via a linker.

3. The composition of claim 2 , wherein said linker is 4-[4-N-maleimidophenyl]butyric acid hydrazide (MBPH).

4. The composition of claim 2 , wherein the linker is releasable or hydrolysable.

5. The composition of claim 1 , wherein said water soluble polymer is selected from the group consisting of polyethylene glycol (PEG), polysialic acid (PSA) and dextran.

6. The composition according to claim 1 , wherein said modified Factor VIII retains at east 60% of native FVIII activity.

7. The composition according to claim 6 , wherein said modified Factor VIII retains at least 70% of native FVIII activity.

8. The composition of claim 1 , wherein said water soluble polymer has a molecular weight of 2,000 to 150,000 Da.

9. The composition of claim 8 , wherein said water soluble polymer has a molecular weight of 5,000 to 50,000 Da.

10. The composition of claim 1 , wherein said water soluble polymer is branched.

11. The composition of claim 1 , wherein said water soluble polymer is linear.

12. The composition of claim 1 , wherein the Factor VIII is a recombinant Factor VIII.

13. The composition of claim 1 , wherein the Factor VIII is a plasmatic Factor VIII.

14. The composition of claim 1 , wherein the composition comprises a plurality of conjugates, each having at least one water soluble polymer bound to a native Factor VIII, said water soluble polymer attached to the modified Factor VIII via one or more carbohydrate moieties, said modified Factor VIII retaining at least 50% of native FVIII activity, and (ii) a pharmaceutically acceptable excipient.

15. The composition of claim 1 , further comprising an unconjugated Factor VIII moiety.

16. A kit comprising a pharmaceutical composition comprising (i) a composition according to claim 1 , and (ii) a pharmaceutically acceptable excipient; packaged in a container with a label that describes use of the pharmaceutical composition in the method of claim 1 .

17. A kit according to claim 16 , wherein the pharmaceutical composition is packaged in a unit dose form.

18. A kit comprising a first container comprising a composition according to claim 1 , and a second container comprising a physiologically acceptable reconstitution solution for said composition in the first container, wherein said kit is packaged with a label that describes use of the pharmaceutical composition in the method of claim 1 .

19. A kit according to claim 18 , wherein the pharmaceutical composition is packaged in a unit dose form.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055188/0953 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2016
From: TURECEK, PETER; SIEKMANN, JUERGEN
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 037642/0106 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED AT REEL: 036359 FRAME: 0631. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 24, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036433/0699 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE S.A.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036359/0631 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036373/0001 →